Bextra Linked to Heart Attack, Stevens-Johnson Syndrome

October 11, 2013

Important Information

ClassAction.org is no longer reviewing claims for this case. The information here is for reference only. Up-to-date information and resources can be found here.

Comments |

At A Glance

This Alert Affects
If you have used Bextra as directed by a doctor and suffered a heart attack, stroke, or serious skin reactions, you may be entitled to compensation.
Damages
Use of Bextra has been shown to produce higher than normal cardiovascular events for patients. This includes heart attacks and strokes. It has also been linked to potentially life threatening skin conditions including Stevens Johnson Syndrome, toxic epidermal necrolysis, and erythema multiforme.
Company(ies)
Pfizer
Additional Details
Bextra is prescription drug used to treat arthritis, menstrual cramps, and associated problems. It is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and helps reduce pain, swelling, and fever without causing stomach irritation.
Date
On April 7, 2005, Pfizer removed Bextra from the market in response to pressure from the FDA.